These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20060802)

  • 1. On the use of cells or membranes for receptor binding: growth hormone secretagogues.
    Pinyot A; Nikolovski Z; Bosch J; Segura J; Gutiérrez-Gallego R
    Anal Biochem; 2010 Apr; 399(2):174-81. PubMed ID: 20060802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsaturated fatty acids prevent desensitization of the human growth hormone secretagogue receptor by blocking its internalization.
    Delhanty PJ; van Kerkwijk A; Huisman M; van de Zande B; Verhoef-Post M; Gauna C; Hofland L; Themmen AP; van der Lely AJ
    Am J Physiol Endocrinol Metab; 2010 Sep; 299(3):E497-505. PubMed ID: 20587751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a.
    Leyris JP; Roux T; Trinquet E; Verdié P; Fehrentz JA; Oueslati N; Douzon S; Bourrier E; Lamarque L; Gagne D; Galleyrand JC; M'kadmi C; Martinez J; Mary S; Banères JL; Marie J
    Anal Biochem; 2011 Jan; 408(2):253-62. PubMed ID: 20937574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-induced changes in the properties of beta-adrenergic receptors on intact S49 lymphoma cells. Time-dependent changes in the affinity of the receptor for agonists.
    Hoyer D; Reynolds EE; Molinoff PB
    Mol Pharmacol; 1984 Mar; 25(2):209-18. PubMed ID: 6142414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine does not bind to the growth hormone secretagogue receptor type-1a (GHS-R1a).
    Carreira MC; Camiña JP; Díaz-Rodríguez E; Alvear-Perez R; Llorens-Cortes C; Casanueva FF
    J Endocrinol; 2006 Oct; 191(1):147-57. PubMed ID: 17065398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations.
    Zhang ZJ; Trivedi BL; de Paulis T; Schmidt DE; Hewlett WA
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):123-32. PubMed ID: 11819030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
    Xu T; Ye F; Wang B; Tian C; Wang S; Shu K; Guo D; Lei T
    Neuro Endocrinol Lett; 2010; 31(1):147-54. PubMed ID: 20150876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioligand-binding methods for membrane preparations and intact cells.
    Bylund DB; Deupree JD; Toews ML
    Methods Mol Biol; 2004; 259():1-28. PubMed ID: 15250483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a scintillation proximity assay binding method for the human 5-hydroxytryptamine 6 receptor using intact cells.
    Carrick T; Kowal D; Nawoschik S; Zhang G; Chan K; Dunlop J
    Anal Biochem; 2008 Oct; 381(1):27-32. PubMed ID: 18601889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transduction mechanism of the seabream growth hormone secretagogue receptor.
    Chan CB; Leung PK; Wise H; Cheng CH
    FEBS Lett; 2004 Nov; 577(1-2):147-53. PubMed ID: 15527776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
    Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
    Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New active series of growth hormone secretagogues.
    Guerlavais V; Boeglin D; Mousseaux D; Oiry C; Heitz A; Deghenghi R; Locatelli V; Torsello A; Ghé C; Catapano F; Muccioli G; Galleyrand JC; Fehrentz JA; Martinez J
    J Med Chem; 2003 Mar; 46(7):1191-203. PubMed ID: 12646029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S; Sallés J
    Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations.
    Moulin A; Demange L; Bergé G; Gagne D; Ryan J; Mousseaux D; Heitz A; Perrissoud D; Locatelli V; Torsello A; Galleyrand JC; Fehrentz JA; Martinez J
    J Med Chem; 2007 Nov; 50(23):5790-806. PubMed ID: 17927165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence against adenosine analogues being agonists at the growth hormone secretagogue receptor.
    Johansson S; Fredholm BB; Hjort C; Morein T; Kull B; Hu PS
    Biochem Pharmacol; 2005 Aug; 70(4):598-605. PubMed ID: 15979585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities.
    Liu G; Fortin JP; Beinborn M; Kopin AS
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1036-43. PubMed ID: 17596538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand.
    Costa T; Ogino Y; Munson PJ; Onaran HO; Rodbard D
    Mol Pharmacol; 1992 Mar; 41(3):549-60. PubMed ID: 1312216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intact cell binding properties of cells expressing altered beta-adrenergic receptors.
    Zhu SJ; Toews ML
    Mol Pharmacol; 1994 Feb; 45(2):255-61. PubMed ID: 7906855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.